why choose us

First received: October 27, 2023

Clinical Trial: A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-segmental Vitiligo

Study Type: INTERVENTIONAL


Official Title: A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental Vitiligo

Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and tolerability of MK-6194 in participants with non-segmental vitiligo.The primary hypothesis is that at least 1 MK-6194 dose is superior to placebo with regards to percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24.

Read more